Please confirm your editon.
Want to change your edition?Go to your My INN page.
Silo Wellness Adds Biotech Research Expertise to its Psychedelic Wellness Portfolio
Dyscovry’s research and development work on psilocybin for irritable bowel syndrome brings pharmaceutical expertise into Silo Wellness’ psychedelic wellness platform.
Silo Wellness Adds Biotech Research Expertise to its Psychedelic Wellness Portfolioyoutu.be
Silo Wellness’s (CSE:SILO,OTCQB:SILFF) acquisition of Toronto-based biotech firm Dyscovry Science provides an opportunity for the company to expand into the pharmaceutical space and biotech research, said Bradley Dottin, founder and president of Dyscovry Science.
Dyscovry has been focused on biosynthetic manufacturing of psilocybin and its derivatives targeting a physiological condition called irritable bowel syndrome, a common disorder in the gastrointestinal tract affecting up to 15 percent of the world’s population. Silo Wellness is a psychedelic wellness company focused on researching psilocybin and developing psychedelic wellness facilities in jurisdictions with no legal barriers.
“So what we bring here is threefold," Dottin said. "We have a biosynthetic pathway, which allows us to work towards the production of psilocybin. And we also have a therapeutic angle with an indication specifically for irritable bowel syndrome coming alongside. And those are the unique factors.
“On top of this … we've structured collaborations and partnerships with strategic partners, including the Canadian federal government research labs, to allow us to push this agenda for combining our strength with a deep breadth of expertise on the other side, but more importantly, the design and approach of thinking downstream … to ultimately be able to produce this in a large scale."
Through research collaboration with Canadian government research laboratories, Dyscovry intends to develop a biotech process for the production of psilocybin and its potential molecule derivatives. This adds pharmaceutical research and development to Silo’s patent-pending metered dosing formulations.
Watch the full interview with Dyscovry Science president and founder Bradley Dottin.
Disclaimer: This interview is sponsored by Silo Wellness’s (CSE:SILO,OTCQB:SILFF). This interview provides information which was sourced by the Investing News Network (INN) and approved by Silo Wellness in order to help investors learn more about the company. Silo Wellness is a client of INN. The company’s campaign fees pay for INN to create and update this interview.
INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.
The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Silo Wellness and seek advice from a qualified investment advisor.
This interview may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, receipt of property titles, etc. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. The issuer relies upon litigation protection for forward-looking statements. Investing in companies comes with uncertainties as market values can fluctuate.